adenosine diphosphate ribose has been researched along with temozolomide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hirota, K; Ibrahim, MA; Masutani, M; Ooka, M; Sasanuma, H; Shimizu, N; Takeda, S; Tsuda, M; Yamada, K; Yamada, S | 1 |
| Bindra, RS; Glazer, PM; Pashankar, F; Singh, C; Vasquez, JC | 1 |
2 other study(ies) available for adenosine diphosphate ribose and temozolomide
| Article | Year |
|---|---|
XRCC1 counteracts poly(ADP ribose)polymerase (PARP) poisons, olaparib and talazoparib, and a clinical alkylating agent, temozolomide, by promoting the removal of trapped PARP1 from broken DNA.
Topics: Adenosine Diphosphate Ribose; Alkylating Agents; DNA; DNA Damage; DNA Repair; Methyl Methanesulfonate; Phthalazines; Piperazines; Poisons; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Temozolomide | 2022 |
Metastatic and multiply relapsed SDH-deficient GIST and paraganglioma displays clinical response to combined poly ADP-ribose polymerase inhibition and temozolomide.
Topics: Adenosine Diphosphate Ribose; DNA Repair; Gastrointestinal Stromal Tumors; Humans; Paraganglioma; Poly(ADP-ribose) Polymerases; Temozolomide | 2023 |